Oxymatrine

Oxymatrine is a quinolizidine alkaloid extracted from the root of Sophora flavescens that exerts antiviral, anti-inflammatory, and hepatoprotective effects primarily by inhibiting NF-κB signaling and suppressing HBV DNA replication. Clinical evidence supports its use as an adjunct therapy in chronic hepatitis B, where it reduces viral load and improves liver enzyme normalization.

Origin & History

Oxymatrine is a quinoline alkaloid extracted from the root of the plant Sophora flavescens, a traditional Chinese medicinal herb. It belongs to the matrine-type alkaloid chemical class and is primarily obtained through solvent extraction methods from the plant material.

Historical & Cultural Context

Oxymatrine is derived from Sophora flavescens, a plant used in Traditional Chinese Medicine for its therapeutic effects. It is commonly applied in China for treating chronic hepatitis B, often in combination with modern antiviral therapies.

Health Benefits

• Significantly reduces YMDD mutation incidence in chronic hepatitis B patients when combined with lamivudine, according to a meta-analysis of 16 RCTs.[1] • Improves ALT normalization and increases HBeAg/HBV DNA negative conversion rates in CHB patients, as shown in a Phase III RCT.[2] • Enhances sustained virological response in CHB when used with interferon, as reported in a meta-analysis of 11 RCTs.[4] • Demonstrates anti-inflammatory effects in preclinical rheumatoid arthritis models by reducing TNF-α and IL-17A.[3] • Provides organ and tissue protection by regulating inflammatory pathways.[9]

How It Works

Oxymatrine suppresses hepatitis B virus replication by downregulating HBV covalently closed circular DNA (cccDNA) transcription and inhibiting the NF-κB and TLR4/NF-κB signaling cascades, thereby reducing pro-inflammatory cytokine release including TNF-α and IL-6. It also modulates Th1/Th2 immune balance by upregulating IFN-γ production, enhancing host antiviral immunity. Additionally, oxymatrine inhibits hepatic stellate cell activation via the TGF-β1/Smad pathway, contributing to its anti-fibrotic properties.

Scientific Research

Clinical trials and meta-analyses have demonstrated oxymatrine's efficacy in treating chronic hepatitis B. Notable studies include a meta-analysis of 16 RCTs (n=1569) and another Phase III RCT (PMID: 16206677). Additionally, a meta-analysis of 11 RCTs (PMID: 27236147) highlights its virological benefits.

Clinical Summary

A meta-analysis of 16 randomized controlled trials found that oxymatrine combined with lamivudine significantly reduced YMDD mutation incidence compared to lamivudine monotherapy in chronic hepatitis B (CHB) patients. A Phase III RCT demonstrated improved ALT normalization and increased HBeAg and HBV DNA negative conversion rates versus placebo. Most trials are conducted in Chinese populations with sample sizes ranging from 60 to 300 participants, and while results are promising, larger multicenter international trials are needed to confirm generalizability. Evidence quality is moderate; publication bias and short follow-up durations remain limitations of the current body of research.

Nutritional Profile

Oxymatrine is a quinolizidine alkaloid (molecular formula: C₁₅H₂₄N₂O₂; molecular weight: 264.36 g/mol) extracted primarily from the root of Sophora flavescens (Ku Shen). It is not a nutritional ingredient and contains no meaningful macronutrients, micronutrients, vitamins, minerals, or dietary fiber in pharmacological doses. As a purified bioactive compound, it is administered as an active pharmaceutical/nutraceutical agent rather than a food source. Typical therapeutic concentrations used in clinical studies range from 400–600 mg/day (injectable or oral forms). The compound exists as the N-oxide form of matrine, with the oxygen bridge at the N-1 position conferring distinct pharmacokinetics. Oral bioavailability is moderate, estimated at approximately 30–50% in animal models, with hepatic first-pass metabolism converting a portion back to matrine. Peak plasma concentration (Tmax) is reached within 1–2 hours after oral administration. The compound is primarily distributed to the liver, kidney, and lung tissues, which is pharmacologically relevant to its hepatoprotective applications. No protein, carbohydrate, fat, or fiber content is applicable at standard therapeutic doses (typically 100–200 mg per unit dose in injectable preparations or 0.1–0.2 g oral tablets).

Preparation & Dosage

Clinically studied dosages in CHB involve intravenous/intramuscular injections plus oral capsules, but specific mg amounts are not detailed. In rheumatoid arthritis rat models, 25–100 mg/kg doses were used. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Lamivudine, Interferon, Tiopronin, Curcumin, Resveratrol

Safety & Interactions

Oxymatrine is generally well tolerated at therapeutic doses (typically 600–1800 mg/day of standardized extract), with the most commonly reported side effects being mild gastrointestinal discomfort, nausea, and dizziness. At higher doses or with prolonged use, reversible cardiotoxicity including QT prolongation and arrhythmia has been observed in animal models, warranting caution in patients with pre-existing cardiac conditions. Drug interactions with lamivudine appear additive rather than antagonistic in clinical settings, but co-administration with other hepatically metabolized drugs should be monitored due to potential CYP450 modulation. Safety data in pregnancy and lactation are insufficient, and its use is not recommended in these populations.